{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:56:22Z","timestamp":1787507782812,"version":"build-2736575974"},"reference-count":44,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jfma.2022.06.003","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T07:55:09Z","timestamp":1656662109000},"page":"2556-2565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of relative dose intensity of R-CCOP regimen in elderly patients with diffuse large B-cell lymphoma in China"],"prefix":"10.1016","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3583-5078","authenticated-orcid":false,"given":"Hongye","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jfma.2022.06.003_bib1","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1002\/cam4.3037","article-title":"Improving survival of 3760 patients with lymphoma: experience of an academic center over two decades","volume":"9","author":"Liu","year":"2020","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.jfma.2022.06.003_bib2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13045-019-0785-7","article-title":"Burden of lymphoma in China, 2006-2016: an analysis of the global burden of disease study 2016","volume":"12","author":"Liu","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"4","key":"10.1016\/j.jfma.2022.06.003_bib3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jfma.2022.06.003_bib4","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","article-title":"Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network","volume":"105","author":"Smith","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jfma.2022.06.003_bib5","unstructured":"Cancer stat facts: diffuse large B-cell lymphoma. NIH, Natl Cancer Institute, SEER Data. https:\/\/www.seer.cancer.gov\/."},{"issue":"18","key":"10.1016\/j.jfma.2022.06.003_bib6","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jfma.2022.06.003_bib7","first-page":"1833","article-title":"Severe neutropenia and relative dose intensity among patients<65 and \u226565 years with non-Hodgkin's lymphoma receiving CHOP-based chemotherapy","volume":"22","author":"Schwartzberg","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jfma.2022.06.003_bib8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s12012-020-09589-z","article-title":"Chemotherapy with a pegylated liposomal doxorubicin-containing regimen in newly diagnosed Hodgkin lymphoma patients","volume":"21","author":"Liu","year":"2020","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.jfma.2022.06.003_bib9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejca.2016.02.004","volume":"58","author":"Fridrik","year":"2016","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.jfma.2022.06.003_bib10","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/hon.2764","article-title":"Nonpeghylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity","volume":"38","author":"Rigacci","year":"2020","journal-title":"Hematol Oncol"},{"issue":"10","key":"10.1016\/j.jfma.2022.06.003_bib11","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1080\/10428190600799946","article-title":"CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma","volume":"47","author":"Zaja","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.jfma.2022.06.003_bib12","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.clml.2014.09.001","article-title":"Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial","volume":"15","author":"Oki","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.jfma.2022.06.003_bib13","first-page":"180","article-title":"Efficacy and safety of CDOP regimen with pegylated liposomal doxorubicin \u00b1 rituximab in treating diffuse large B-cell lymphoma","volume":"61","author":"Gao","year":"2019","journal-title":"Minerva Med"},{"issue":"1","key":"10.1016\/j.jfma.2022.06.003_bib14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hon.2386","article-title":"Combination of rituximab and nonpegylated liposomal doxorubicin (R-NPLD) as front-line therapy for aggressive non-Hodgkin lymphoma (NHL) in patients 80 years of age or older: a single-center retrospective study","volume":"36","author":"Ricciuti","year":"2018","journal-title":"Hematol Oncol"},{"issue":"9","key":"10.1016\/j.jfma.2022.06.003_bib15","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1182\/bloodadvances.2021004665","article-title":"Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review","volume":"5","author":"Bataillard","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jfma.2022.06.003_bib16","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/cam4.2008","article-title":"The average relative dose intensity of R-CHOP is an independent factor determining favorable overall survival in diffuse large B-cell lymphoma patients","volume":"8","author":"D\u0142ugosz-Danecka","year":"2019","journal-title":"Cancer Med"},{"issue":"21","key":"10.1016\/j.jfma.2022.06.003_bib17","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1200\/JCO.2004.03.213","article-title":"Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study","volume":"22","author":"Lyman","year":"2004","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jfma.2022.06.003_bib18","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1007\/s00432-020-03279-7","article-title":"Impact of comorbidity and relative dose intensity on outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP","volume":"146","author":"Yamamoto","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"issue":"20","key":"10.1016\/j.jfma.2022.06.003_bib19","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jfma.2022.06.003_bib20","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","article-title":"New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality","volume":"57","author":"Sundararajan","year":"2004","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"10.1016\/j.jfma.2022.06.003_bib21","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chron Dis"},{"issue":"7","key":"10.1016\/j.jfma.2022.06.003_bib22","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00432-010-0973-x","article-title":"Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma","volume":"137","author":"Kobayashi","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"10.1016\/j.jfma.2022.06.003_bib23","first-page":"1860","article-title":"Report of the Committee on Hodgkin's disease staging classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"issue":"14","key":"10.1016\/j.jfma.2022.06.003_bib24","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jfma.2022.06.003_bib25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.jfma.2022.06.003_bib26","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jfma.2022.06.003_bib27","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/bimj.200900039","article-title":"A note on variance estimation of the Aalen-Johansen estimator of the cumulative incidence function in competing risks, with a view towards left-truncated data","volume":"52","author":"Allignol","year":"2010","journal-title":"Biom J"},{"key":"10.1016\/j.jfma.2022.06.003_bib28","series-title":"Regression modeling strategies: with applications to linear models, Logistic Regression, and Survival Analysis","author":"Harrell","year":"2001"},{"issue":"1","key":"10.1016\/j.jfma.2022.06.003_bib29","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-019-0706-9","article-title":"Mortality of lymphoma and myeloma in China, 2004-2017: an observational study","volume":"12","author":"Liu","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jfma.2022.06.003_bib30","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1756-9966-28-116","article-title":"Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma","volume":"28","author":"Terada","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.jfma.2022.06.003_bib31","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1182\/blood.V128.22.4211.4211","article-title":"Retrospective study of the optimal CHOP dose for elderly patients with diffuse large B-cell lymphoma","volume":"128","author":"Ono","year":"2016","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.jfma.2022.06.003_bib32","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1182\/blood-2018-99-110699","article-title":"Factors relating to the favorable outcome in reduced-dose R-CHOP therapy for elderly DLBCL patients","volume":"132","author":"Ono","year":"2018","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.jfma.2022.06.003_bib33","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1002\/cncr.28350","article-title":"Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study","volume":"119","author":"Martin","year":"2013","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.jfma.2022.06.003_bib34","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3109\/10428194.2014.953142","article-title":"Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL)","volume":"56","author":"Tucci","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.jfma.2022.06.003_bib35","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11864-018-0565-6","article-title":"Treating diffuse large B cell lymphoma in the very old or frail patients","volume":"19","author":"Kumar","year":"2018","journal-title":"Curr Treat Options Oncol"},{"issue":"9","key":"10.1016\/j.jfma.2022.06.003_bib36","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00277-010-0956-7","article-title":"Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma","volume":"89","author":"Hirakawa","year":"2010","journal-title":"Ann Hematol"},{"issue":"S2","key":"10.1016\/j.jfma.2022.06.003_bib37","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/hon.5_2629","article-title":"ROBUST: first report of phase III randomized study of lenalidomide\/R-CHOP (R2-CHOP) vs placebo\/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma","volume":"37","author":"Vitolo","year":"2019","journal-title":"Hematol Oncol"},{"issue":"2","key":"10.1016\/j.jfma.2022.06.003_bib38","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.jfma.2022.06.003_bib39","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(13)70122-0","article-title":"Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial","volume":"14","author":"Delarue","year":"2013","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.jfma.2022.06.003_bib40","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.jfma.2022.06.003_bib41","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2020-136255","article-title":"Single-agent Mosunetuzumab is a promising safe and efficacious chemotherapy-free regimen for elderly\/unfit patients with previously untreated diffuse large B-cell lymphoma","volume":"136","author":"Olszewski","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jfma.2022.06.003_bib42","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13046-019-1076-4","article-title":"Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma","volume":"38","author":"He","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.jfma.2022.06.003_bib43","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","article-title":"A safe and potent anti-CD19 CAR T cell therapy","volume":"25","author":"Ying","year":"2019","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.jfma.2022.06.003_bib44","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/cam4.3686","article-title":"Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed\/refractory large B-cell lymphoma in China","volume":"10","author":"Ying","year":"2021","journal-title":"Cancer Med"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092966462200242X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092966462200242X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:48:44Z","timestamp":1760539724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092966462200242X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S092966462200242X"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2022.06.003","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of relative dose intensity of R-CCOP regimen in elderly patients with diffuse large B-cell lymphoma in China","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2022.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}